Related Experiment Videos
Rheumatoid factor in patients with systemic lupus erythematosus
D Feldman1, D Feldman, E Ginzler
1Department of Medicine, State University of New York, Brooklyn 11203.
The Journal of Rheumatology
|May 1, 1989
Summary
Rheumatoid factor (RF) in systemic lupus erythematosus (SLE) patients may indicate better immune function. This suggests RF may offer protection against severe SLE complications and herpes zoster.
Area of Science:
- Immunology
- Rheumatology
- Infectious Disease
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
- The role of rheumatoid factor (RF) in SLE pathogenesis and clinical outcomes is not fully understood.
Purpose of the Study:
- To investigate the association between rheumatoid factor (RF) and clinical manifestations in patients with systemic lupus erythematosus (SLE).
Main Methods:
- Survey of 166 SLE patients.
- Sera tested for rheumatoid factor (RF) presence and titers.
- Correlation analysis between RF status and clinical outcomes.
Main Results:
- Fifteen patients had consistent RF positivity (titer ≥ 1:40).
- RF-positive patients showed reduced likelihood of severe SLE manifestations.
- RF positivity was associated with less frequent high-dose steroid or cytotoxic drug use and fewer herpes zoster episodes.
Conclusions:
- Rheumatoid factor (RF) in SLE patients may signify relative immune competence.
- RF positivity might confer partial protection against severe SLE manifestations and herpes zoster.
- Further research is warranted to explore the immunomodulatory role of RF in SLE.